See more news releases in: Health Care & Hospitals, Surveys, Polls and Research
Reportlinker Adds Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013
NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013
http://www.reportlinker.com/p0164998/Oncology-Roadmap-Brand-Spending-Benchmarks-and-Market-Forecast-to-2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire
Comprehensive Forecasts and Detailed Budget Benchmarks new report, "Oncology Roadmap," explores the fiercely competitive oncology market in a way that no other available forecast can match.
Our experienced analysts have reviewed thousands of historical and forecasted data points to provide the most comprehensive oncology market outlook ever.
At the same time, brand budget benchmarks reveal spending in key areas throughout development and launch.
Uncover Oncology Threats and Opportunities
Equip your teams with the most comprehensive forecast of the oncology marketplace -- from today's stalwarts to tomorrow's blockbusters.
Product Breakdown
112 Anti-cancer drugs in all major classes
15 Adjuncts
Product Profile Components
-Product history
-Competitive and strategic positioning
-Market growth opportunities
-Sales history and projections
-Drug's materiality to company
Budget Brand Resources for Development and Launch
Track real brand spending from the pre-clinical period through the first year on the market
Brand Spending Benchmarks
-Advertising and promotion
-Medical affairs
-Decision support (market research)
-Market access
Summary
Brand Spending Benchmarks
Average brand spending by budget category:
- Advertising and promotion
- Medical affairs
- Decision support (market research)
- Market access
Average brand spending by development stage:
- Pre-Clinical to phase 2
- Phase 3a
- Phase 3b
- First year on the market
Product Profiles by Class
Brand Information
- Brand and generic name
- Drug class
- Delivery mechanism
- Line of treatment
Sales Data
- Historical/current sales
- Forecasted sales
Approved Indications
- Current Product Development Phases
- Competitive and Strategic Positioning
- Market Opportunities and Brand Growth
- Patent, Generic and Litigation Information
Oncology Indication Analysis
- Current sales, major drugs and important companies
- Forecasted sales and assessment of future drugs and market players
- Pipeline development status
- Major market events, changes in treatments, patent expirations, etc.
Companies' Oncology Portfolios
- Current sales, major drugs and important companies
- Forecasted sales and assessment of future drugs and market players
- Pipeline development status
Companies mentioned
Amgen AstraZeneca Bristol-Myers Squibb Celgene Eli Lilly GlaxoSmithKline Johnson & Johnson Merck Novartis Pfizer Roche and Genentech Sanofi-Aventis Schering-Plough
To order this report:
Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013
http://www.reportlinker.com/p0164998/Oncology-Roadmap-Brand-Spending-Benchmarks-and-Market-Forecast-to-2013.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire
More market research reports here!
Nicolas Bombourg Reportlinker Email: nbo@reportlinker.com US: (805)652-2626 Intl: +1 805-652-2626
SOURCE Reportlinker
Back to top
RELATED LINKS
http://www.reportlinker.com
